rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12345678910111213...1617»
  • ||||||||||  Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
    Review, Journal:  Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews. (Pubmed Central) -  Jul 27, 2022   
    The use of ChEIs, including rivastigmine, galantamine, and donepezil, as well as memantine has demonstrated a positive impact on improving cognitive outcomes of AD patients, but no considerable effects were found for immunotherapies. Melatonin, statins, antihypertensive drugs, antidiabetic agents, Cerebrolysin, psychostimulants, and some herbal drugs such as Danggui-Shaoyao-San and Ginkgo biloba seem to be effective in improving cognitive function of AD patients, but the evidence in this regard is limited.
  • ||||||||||  rivastigmine / Generic mfg.
    Biomarker, Journal, IO biomarker:  Sarcococca saligna ameliorated D-galactose induced neurodegeneration through repression of neurodegenerative and oxidative stress biomarkers. (Pubmed Central) -  Jul 27, 2022   
    Alzheimer's disease model was prepared by administration of D-galactose subcutaneous injection100 mg/kg and it was treated with rivastigmine (100 mg/kg, orally) and plant extract for 42 days...saligna at 500-1000 mg/kg considerably recovered the mRNA expression of neurodegenerative and neuro-inflammatory biomarkers, also evident from histopathological analysis. These findings suggest that S. saligna could be applicable in cure of Alzheimer's disease.
  • ||||||||||  donepezil one-month depot (GB-5001) / G2GBIO
    Preclinical, Journal:  Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice. (Pubmed Central) -  Jul 27, 2022   
    Surprisingly, we observed that intraperitoneal/oral injection of donepezil treatment significantly increased tau phosphorylation at Thr212 in 5xFAD mice. Taken together, these data suggest that intraperitoneal injection of donepezil suppresses Aβ pathology but not tau pathology in 5xFAD mice.
  • ||||||||||  neflamapimod (VX-745) / EIP Pharma
    Review, Journal:  Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. (Pubmed Central) -  Jul 17, 2022   
    Levodopa may provide modest benefit in treating motor symptoms and zonisamide in adjunct to low-dose levodopa helps with parkinsonism...Phase II trial results for neflamapimod show promising results. Due to heterogeneity of symptoms and underlying pathophysiology, there is a need for new biomarker strategies and improved definitions of outcome measures for Lewy body dementia drug trials.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Iranian thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model. (Pubmed Central) -  Jun 29, 2022   
    Likewise, MDA and neurodegeneration increased in the AD group while in all preventive and therapeutic group's especially Iranian thyme honey, they decreased and conversely, total antioxidant and number of normal cells elevated and healthy neurons were observed in all parts of the hippocampus and cortex. Our results despite the limitations showed the powerful antioxidant properties and cytoprotective effects of Iranian thyme honey vs rivastigmine on hippocampal neurons that consequently enhanced memory and if advanced diagnostic tests in human clinical patients show other more pronounced effects, we have certainly started a key and targeted strategy.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen
    Review, Journal:  Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. (Pubmed Central) -  Jun 25, 2022   
    In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
  • ||||||||||  donepezil / Generic mfg., rivastigmine / Generic mfg.
    Review, Journal:  Interventions for preventing falls in Parkinson's disease. (Pubmed Central) -  Jun 14, 2022   
    Further research in the form of large, high-quality RCTs are required to determine the relative impact of different types of exercise and different levels of supervision on falls, and how this could be influenced by disease severity. Further work is also needed to increase the certainty of the effects of medication and further explore falls prevention education interventions both delivered alone and in combination with exercise.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Retrospective data, Journal:  Targeting the Beta-2-Adrenergic Receptor and the Risk of Developing Alzheimer's Disease: A Retrospective Inception Cohort Study. (Pubmed Central) -  Jun 9, 2022   
    Conclusions are limited by paucity of research; but fortunately, a large randomized controlled trial is ongoing, and more are needed to truly determine the efficacy of AChEIs in helping with recovery from TBI. These findings suggest that exposure to non-selective βAR antagonists is associated with an increased risk for developing AD whereas there may be a decreased risk for developing AD after exposure to selective β2AR agonists.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Journal:  A comprehensive computational perspective in drug discovery for Alzheimer's disease. (Pubmed Central) -  Jun 8, 2022   
    This chapter considers a wide range targets for Alzheimer's disease and current advances in the discovery of disease inhibitors. And also brief in-silico studies were highlighted and included to know how the theoretical lead is achievable in AD medication discovery.
  • ||||||||||  Cognex (tacrine) / Shionogi
    Review, Journal:  Determination of Anti-Alzheimer's Disease Activity of Selected Plant Ingredients. (Pubmed Central) -  Jun 5, 2022   
    This study also aims to highlight species with assessed efficacy, usable plant parts and the most active plant components in order to identify species and compounds of interest for further study. Future research directions are suggested and recommendations made to expand the use of medicinal plants, their formulations and plant-derived active compounds to prevent, mitigate and treat Alzheimer's disease.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Biomarker, Review, Journal:  Pharmacogenetic studies in Alzheimer disease. (Pubmed Central) -  May 29, 2022   
    Potential pharmacogenetic biomarkers for AD have been identified; however, it is still necessary to conduct further research into other populations and to identify new biomarkers. This information could assist in predicting patient response to these drugs and contribute to better treatment decision-making in a context as complex as ageing.
  • ||||||||||  Nuplazid (pimavanserin) / Acadia Pharma
    Journal:  Management of Psychiatric Disorders in Patients with Parkinson's Diseases. (Pubmed Central) -  May 24, 2022   
    Pramipexole, a dopamine agonist (DA), is reported to cause improvement in the symptoms of decreased willingness in apathy...The psychiatric symptoms in patients with PD are highly prevalent, and their management should be included in the basic treatment algorithm for PD. This paper summarizes common psychiatric symptoms/disorders in PD and their management approaches.
  • ||||||||||  Journal:  The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer's Disease. (Pubmed Central) -  May 21, 2022   
    The combination of rivastigmine and antipsychotic drugs (apart from PNF) enhanced AChE inhibition...The antioxidative properties of antipsychotics were also proved in human umbilical vein endothelial cells (HUVEC); all tested drugs were found to significantly increase cell viability. In the case of astrocytes, BNP, PNF, PIM and PROM showed antioxidant potential.
  • ||||||||||  Cognex (tacrine) / Shionogi
    Review, Journal:  Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives. (Pubmed Central) -  May 21, 2022   
    However, there is still a huge challenge in the field of neuroprotection, but in the context of unravelling the details of the PI3K/AKT pathway, a new scenario has emerged for the development of more efficient drugs that act on multiple protein targets. Thus, the mechanisms by which ChEI can promote neuroprotective effects and prospects for the development of new drug candidates for the treatment of AD are discussed in this review.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  An In Vivo Investigation of Ascorbic Acid Tethered Polymeric Nanoparticles for Effectual Brain Transport of Rivastigmine. (Pubmed Central) -  May 18, 2022   
    The results of this study highlight the potential of using thermosensitive in situ hydrogels containing lipid-based nanosystems to improve the nose-to-brain delivery of rivastigmine , providing a promising alternative therapeutic option to advance the management of Alzheimer's disease. As a consequence, the findings revealed that using ascorbic acid grafted PLGA-b-PEG NPs to deliver bioactives to the brain is a potential strategy.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Increased MYD88 blood transcript in a mouse model of Alzheimer's disease. (Pubmed Central) -  May 10, 2022   
    As a consequence, the findings revealed that using ascorbic acid grafted PLGA-b-PEG NPs to deliver bioactives to the brain is a potential strategy. Our results suggest that MYD88 might be a promising blood biomarker to monitor AD progression.
  • ||||||||||  Cognex (tacrine) / Shionogi
    Journal:  Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease. (Pubmed Central) -  May 6, 2022   
    This review comprises the many hybrids and non-hybrid forms of heteroaromatic and non-heteroaromatic compounds that were designed and evaluated for AchE inhibition by Ellman's method of assay. These novel compounds may assist the future perspectives in the discovery of novel moieties against Alzheimer's disease by the inhibition of AchE.
  • ||||||||||  Myrbetriq (mirabegron) / Astellas
    Journal:  Risk of overactive bladder associated with cholinesterase inhibitors in dementia. (Pubmed Central) -  May 6, 2022   
    The study found that the risk of OAB varies across individual ChEIs with an increased risk of OAB with donepezil compared to rivastigmine. The study findings suggest the need to understand and manage medication-related morbidity in older adults with dementia.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Observational data, Journal:  Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM. (Pubmed Central) -  May 6, 2022   
    A 12-month persistence analysis showed values of approximately 50% for donepezil and memantine and approximately 40% for rivastigmine and galantamine. There were differences in the prescribing pattern and persistence among anti-dementia medications from database using the Observational Medical Outcome Partnership Common Data Model on the Federated E-health Big Data for Evidence Renovation Network platform in Korea.